Diseases of the retina are among the leading causes of irreversible blindness.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Ophthalmology and OptometryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis.Lancet Glob Health. 2017; 5: e888-e897
- Global estimates of visual impairment: 2010.Br J Ophthalmol. 2012; 96: 614-618
- Wet age-related macular degeneration.Nat Rev Drug Discov. 2005; 4: 711-712
- Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases.Graefes Arch Clin Exp Ophthalmol. 2017; 255: 1259-1273
- Risks of intravitreous injection: a comprehensive review.Retina. 2004; 24: 676-698
- Nanoparticles for drug delivery to the anterior segment of the eye.Adv Drug Deliv Rev. 2017; 122: 31-64
- Drug delivery devices for retinal diseases.Adv Drug Deliv Rev. 2017; ([pii:S0169-409X(17)30099-6])
- Advances in ocular drug delivery: emphasis on the posterior segment.Expert Opin Drug Deliv. 2014; 11: 1647-1660
- Drug delivery to the posterior segment from drops.Surv Ophthalmol. 2002; 47: S41-S52
- Posterior sub-Tenon’s triamcinolone injections in the treatment of uveitis.Eye. 1998; 12: 679-685
- Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema.Clin Exp Ophthalmol. 2007; 35: 713-718
- Periocular routes for retinal drug delivery.Expert Opin Drug Deliv. 2004; 1: 99-114
- Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.Invest Ophthalmol Vis Sci. 2010; 51: 5403-5420
- Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry.Invest Ophthalmol Vis Sci. 2007; 48: 2230-2237
- Principles of pharmacology in the eye.Br J Pharmacol. 2017; 174: 4205-4223
- The eye and the heart.Eur Heart J. 2013; 34: 1270-1278
- Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity.Invest Ophthalmol Vis Sci. 2005; 46: 641-646
- Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium.Pharm Res. 2007; 24: 2063-2070
- Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis.Vet Ophthalmol. 2010; 13: 294-300
- Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles.Invest Ophthalmol Vis Sci. 2013; 54: 2483-2492
- Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness.Sci Transl Med. 2010; 2: 21ra16
- Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.Mol Vis. 2009; 15: 267-275
- Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period.J Ocul Pharmacol Ther. 2004; 20: 269-275
- The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy.Cent Eur J Immunol. 2016; 41: 311
- Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure–pharmacokinetic relationships (QSPKR).Pharm Res. 2009; 26: 1236
- Complications of intravitreal injection of triamcinolone acetonide.Can J Ophthalmol. 2005; 40: 63-68
- Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update.Retina. 2011; 31: 4-12
- Management of pseudophakic cystoid macular edema.Surv Ophthalmol. 2015; 60: 123-137
- Pseudophakic cystoid macular edema: update 2016.Clin Interv Aging. 2016; 11: 1221-1229
- Nepafenac a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers.Inflammation. 2000; 24: 371-384
- Topical nepafenac inhibits ocular neovascularization.Invest Ophthalmol Vis Sci. 2003; 44 (52): 409-415
- Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%.J Cataract Refract Surg. 2008; 34: 57-63
- Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.Acta Ophthalmol Scand. 2007; 85: 598-602
- Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema.Invest Ophthalmol Vis Sci. 2011; 52: 7944-7948
- Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.J Cell Physiol. 2008; 216 (53): 29-37
- Mecamylamine suppresses basal and nicotine-stimulated choroidal neovascularization.Invest Ophthalmol Vis Sci. 2008; 49: 1705-1711
- A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications.Ophthalmology. 1997; 104: 2003-2008
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration.N Engl J Med. 2011; 364: 1897-1908
- A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.Am J Ophthalmol. 2009; 148: 43-58.e1
- Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to age-related macular degeneration.Retina. 2012; 32: 293-298
- Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration.Retina. 2011; 31: 26-30
- Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.Ophthalmology. 2009; 116: 1740-1747
- Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug.Br J Ophthalmol. 2012; 96: 1157-1158
- Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome.Ophthalmology. 1991; 98: 1348-1355
- Antiviral activity and mechanism of action of ganciclovir.Clin Infect Dis. 1988; 10: S490-S494
- High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis.Am J Ophthalmol. 2001; 131: 396-397
- Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.Am J Ophthalmol. 2005; 139: 135-140
- Biodegradable implants for sustained drug release in the eye.Pharm Res. 2010; 27: 2043-2053
- Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema.Eur J Ophthalmol. 2016; 26: 454-459
- Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.Invest Ophthalmol Vis Sci. 2011; 52: 80-86
- Drug delivery systems to the posterior segment of the eye: implants and nanoparticles.Bionanoscience. 2016; 6: 276-283
- Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant.Arch Ophthalmol. 1994; 112: 1531
- Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant.N Engl J Med. 1997; 337: 83-90
- Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.Ophthalmology. 2006; 113: 1020-1027
- Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.Invest Ophthalmol Vis Sci. 2000; 41: 3569-3575
- Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results.Arch Ophthalmol. 2008; 126: 1191-1201
- Implantable posterior segment drug delivery devices; novel alternatives to currently available treatments.J Ophthalmic Vis Res. 2009; 4: 191-193
- Fluocinolone acetonide intravitreal implant 0.19 mg (ILUVIEN®): a review in diabetic macular edema.Drugs. 2017; 77: 575-583
- Drug delivery to the posterior segment of the eye.Drug Discov Today. 2011; 16: 270-277
Dugel PU, Eliott D, Cantrill HL, et al. I-Vation™ TA: 24-month clinical results of the Phase I safety and preliminary efficacy study. Proceedings of ARVO 2009 Annual Meeting, Fort Lauderdale, FL, May 3–7, 2009. [E-Abstract: 4332].
- A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.Ophthalmology. 2008; 115 (1449.e1-10): 1447-1449
Lim JI, Hung D, Fung AE, et al. One year results of a phase 1 study evaluating the safety and evidence of efficacy of a single intravitreal injection of the Verisome TM liquid drug delivery system for sustained release of low-dose triamcinolone (IBI-20089) in eyes with cystoid macular edema. In Proceedings of ARVO 2010 Annual Meeting, Fort Lauderdale, FL, May 2–6, 2010. [E-Abstract: 6396].
- Sustained release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular edema in retinal vein occlusion.Ophthalmology. 2011; 118: 1416-1422
- One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD.Br J Ophthalmol. 2015; 99: 618-623
- Nanostructured thin film polymer devices for constant-rate protein delivery.Nano Lett. 2012; 12: 5355-5361
- Zero-order sustained drug delivery to the retina from a nanoporous film device.Drug Delivery. 2014; 48: 20-21
- In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device.Drug Deliv Transl Res. 2016; 6: 771-780
- Dendritic polymer macromolecular carriers for drug delivery.Curr Opin Chem Biol. 2002; 6: 466-471
- Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties.Nanomedicine. 2011; 6: 1063-1084
- Dendrimers as a promising tool in ocular therapeutics: latest advances and perspectives.Int J Pharm. 2016; 511: 359-366
- In vitro/in vivo evaluation of dexamethasone–PAMAM dendrimer complexes for retinal drug delivery.J Pharm Sci. 2015; 104: 3814-3823
- Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity.Gene Ther. 2005; 12: 1544-1550
- Hydrogels in drug delivery: progress and challenges.Polymer. 2008; 49: 1993-2007
- Injectable hydrogels for ophthalmic applications.J Control Release. 2017; 268: 212-224
- Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.Invest Ophthalmol Vis Sci. 2014; 55: 469
- Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study.Transl Vis Sci Technol. 2015; 4: 5
- An electrochemical intraocular drug delivery device.Sens Actuators A Phys. 2008; 143: 41-48
- Mini drug pump for ophthalmic use.Curr Eye Res. 2010; 35: 192-201
- A self-powered implantable drug-delivery system using biokinetic energy.Adv Mater. 2017; 29: 1605668
- On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device.Lab Chip. 2011; 11: 2744-2752
- Long-acting anti-VEGF delivery.Retina Today. 2014; : 78-80
- Encapsulated cell technology could prevent blindness.Drug Discov Today. 2003; 8: 146-147
- Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa.Invest Ophthalmol Vis Sci. 2002; 43: 3292-3298
- Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntingtons disease.Nature. 1997; 386: 395-399
- Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration.Proc Natl Acad Sci U S A. 2011; 108: 6241-6245
- Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment.Invest Ophthalmol Vis Sci. 2011; 52: 2219-2226
- Iontophoretic drug delivery.Adv Drug Deliv Rev. 2004; 56: 619-658
- Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection.Eur J Pharm Biopharm. 2017; 119: 125-136
- Electrically assisted delivery of macromolecules into the corneal epithelium.Exp Eye Res. 2009; 89: 934-941
- Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina.Mol Ther. 2012; 20: 1559-1570
- Ultrasound-enhanced intrascleral delivery of protein.Int J Pharm. 2010; 401: 16-24
- Overcoming ocular drug delivery barriers through the use of physical forces.Adv Drug Deliv Rev. 2017; ([pii:S0169-409X(17)30189-8])
- Targeted and reversible blood-retinal barrier disruption via focused ultrasound and microbubbles.PLoS One. 2012; 7: e42754
- Choroidal changes after suprachoroidal injection of triamcinolone acetonide in eyes with macular edema secondary to retinal vein occlusion.Am J Ophthalmol. 2018; 186: 144-151
- A self-deploying drug release device using polymeric films.J Biomed Mater Res B Appl Biomater. 2017; 106: 780-786
- Delivery strategies for treatment of age-related ocular diseases: from a biological understanding to biomaterial solutions.J Control Release. 2015; 219: 652-668
- Enhancement of retinal pigment epithelial culture characteristics and subretinal space tolerance of scaffolds with 200 nm fiber topography.Biomaterials. 2014; 35: 2837-2850
Article info
Footnotes
Disclosure: The authors have nothing to disclose.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
